Spark Therapeutics Inc. – IR Site News Releases http://ir.sparktx.com/ Spark Therapeutics Inc. – IR Site News Releases en Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-announces-sponsorship-believe-limiteds-first The Science Fair™ aims to engage and educate patients, families and caregivers affected by bleeding PHILADELPHIA, April 17, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, Wed, 17 Apr 2019 07:30:00 -0400 Spark Therapeutics Inc. – IR Site News Releases 9821 Spark Therapeutics Enters into Definitive Merger Agreement with Roche http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-enters-definitive-merger-agreement-roche Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expected to close in Q2, 2019 PHILADELPHIA , Feb. Mon, 25 Feb 2019 01:00:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9681 Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-reports-2018-financial-results-and-recent PHILADELPHIA , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for 2018 and recent business progress. Tue, 19 Feb 2019 07:30:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9676 Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-host-conference-call-tuesday-feb-19-830-am-et PHILADELPHIA , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 19, 2019 , at 8:30 a.m. Tue, 12 Feb 2019 07:30:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9641 Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™ http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-announces-presentation-preclinical-data-pompe PHILADELPHIA , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the presentation of preclinical data for SPK-3006 for Pompe disease and SPK-1001 for Thu, 31 Jan 2019 07:30:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9626 Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-participate-jp-morgan-healthcare-conference-0 PHILADELPHIA , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo , chief executive officer, will be presenting at 4:30 p.m. Wed, 02 Jan 2019 07:30:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9511 Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-announces-updated-data-spk-8011-ongoing-phase Preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show dramatic reductions in bleeds and infusions for first 12 participants with an encouraging safety profile, as of Nov. 2, 2018 , data cutoff All five participants in the first two dose cohorts, the longest of whom is out 78 Sun, 02 Dec 2018 19:30:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9491 European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations http://ir.sparktx.com/news-releases/news-release-details/european-commission-approves-spark-therapeutics-luxturnar LUXTURNA is first gene therapy for a genetic disease approved in both the U.S. and EU LUXTURNA is first and only gene therapy approved in EU for patients with an inherited retinal disease (IRD)  Spark Therapeutics will manufacture and supply LUXTURNA for Novartis , while Novartis has exclusive Fri, 23 Nov 2018 01:15:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9461 Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-reports-third-quarter-2018-financial-results PHILADELPHIA , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for the third quarter of 2018 and recent business Tue, 06 Nov 2018 07:30:00 -0500 Spark Therapeutics Inc. – IR Site News Releases 9431 Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights http://ir.sparktx.com/news-releases/news-release-details/spark-therapeutics-host-conference-call-tuesday-nov-6-830-am-et PHILADELPHIA , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Nov. 6, 2018 , at 8:30 a.m. Tue, 30 Oct 2018 07:30:00 -0400 Spark Therapeutics Inc. – IR Site News Releases 9416